Objectives: To assess the impact of intravenous ferric carboxymaltose (FCM) on fetal and maternal adverse effects in pregnant women diagnosed with iron deficiency anemia (IDA). Methods: This is a multicenter retrospective study on 472 pregnant women diagnosed with moderate to severe IDA undergoing treatment with FCM between 2019 and 2025 at Careggi University Hospital (Florence) and Vittore Buzzi Children Hospital (Milan). Fetal wellbeing was assessed using computerized cardiotocography (cCTG) or ultrasound, based on gestational age at treatment. Maternal side effects were evaluated through clinical evaluation. Results: cCTG was performed in 377/472 patients (80%), with a mean short-term variability of 10.2 ms. Normal cCTG criteria were met in 98.4% of cases; six patients exhibited transient reduced variability, which resolved following intrauterine resuscitation. Ultrasound assessment was performed in 95 patients (20%), revealing no fetal heart rate abnormalities. Maternal side effects occurred in seven patients (1.4%). Hemoglobin concentrations increased by a median of 1.4 g/dL after five weeks, reaching up to 2.8 g/dL in women with a baseline Hb < 8 g/dL. Conclusions: Our findings support the potential safety and efficacy of intravenous FCM for the treatment of IDA during pregnancy, demonstrating low rates of maternal side effects and no adverse fetal heart rate patterns. However, prospective studies are necessary to confirm these results.
Background/Objectives: Nausea and vomiting of pregnancy (NVP) are common and potentially debilitating symptoms of early pregnancy. However, data on their prevalence and impact in Italy are limited. This survey aimed to assess the frequency of NVP among Italian pregnant women and to evaluate its impact on quality of life. Methods: The survey was conducted in three public university hospitals in Italy during two separate periods. Women with multiple pregnancies or who conceived by medically assisted reproduction were excluded. The Questionnaire for Pregnancy Period, including the Pregnancy-Unique Quantification of Emesis (PUQE), was administered during a face-to-face interview at 18–22 weeks of gestation, coinciding with the morphological ultrasound. A structured telephone follow-up interview was performed within 14 days after delivery. This report presents the final analysis of all valid, completed questionnaires. Results: A total of 532 pregnant women were included (mean age 32.7 ± 4.9 years); 277 (52.1%) were primiparous. Overall, NVP was reported by 66.4% of participants. Nausea alone occurred in 28.0% of women, while nausea overall (with or without vomiting) was reported by 64.3%. Vomiting alone was reported by 2.1% and vomiting overall by 38.4% of participants. Symptoms began at a mean gestational age of 7.0 ± 2.8 weeks, lasted 9.7 ± 5.1 weeks, and were still present at the first interview in 30.3% of cases. More than half of the affected women (51.0%) reported limitations in daily activities, particularly work-related activities. Conclusions: This final analysis confirms a high prevalence of NVP among Italian pregnant women and highlights its substantial negative impact on quality of life. Systematic screening and appropriate management strategies should be considered in routine prenatal care.